• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen Receives Orphan Drug Designation for the Treatment of Melanoma

Jul 18, 2018 | 2018, Press Releases, Scientific

PRESS RELEASE DAROMUN

Philogen Announces Exercise of Options Within the License Agreement With AbbVie in the Field of Immuno-Inflammation

Feb 28, 2018 | 2018, Press Releases, Scientific

PRESS RELEASE, FEBRUARY 28TH 2018

Philogen and the Scripps Research Institute announce research collaboration in the field of DNA-Encoded Chemistry.

Jan 8, 2018 | 2018, Press Releases, Scientific

PRESS RELEASE – PHILOCHEM SCRIPPS

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philogen is pleased to invite you to an upcoming webinar on November 20, 2025, at 15:00 GMT | 16:00 CET.
  • The Board of Directors approves the financial position for the third quarter of 2025
  • Il Consiglio di Amministrazione approva la Posizione Finanziaria Netta relativa al terzo trimestre 2025
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it